Journal of Cancer Genetics And Biomarkers

Aims And Scope

 

The Journal of Cancer Genetics and Biomarkers aims to provide a platform for the dissemination of high-quality research in the field of cancer genetics and biomarkers. The journal publishes original research articles, reviews, and perspectives that focus on the genetic and molecular basis of cancer, and the identification and validation of biomarkers for early detection, diagnosis, prognosis, and treatment of cancer.

 

The journal's scope includes, but is not limited to, the following areas:

 

Cancer genetics: Studies that investigate the genetic and epigenetic changes that contribute to the development and progression of cancer.

 

Cancer genomics: Research that utilizes high-throughput sequencing and other genomic technologies to identify and understand the genetic changes that underlie cancer.

 

Cancer epigenetics: Studies that investigate the role of epigenetic changes, such as DNA methylation and histone modification, in the development and progression of cancer.

 

Cancer biomarkers: Research that aims to identify and validate biomarkers for early detection, diagnosis, prognosis, and treatment of cancer.

 

Cancer personalized medicine: Studies that aim to use genetic and molecular information to develop personalized treatment strategies for cancer patients.

 

Cancer prevention and therapy: Research that investigates the genetic and molecular basis of cancer and develops new treatments and therapies for cancer.

 

Cancer epidemiology and public health: Studies that investigate the genetic, environmental, and lifestyle factors that contribute to the development and progression of cancer, and the impact of cancer on public health.

 

The Journal of Cancer Genetics and Biomarkers welcomes submissions from researchers working in the field of cancer genetics and biomarkers, and aims to be a leading forum for the dissemination of new findings and ideas in this rapidly-evolving field.

 

JCGB encourages the submission of manuscripts from all areas of cancer research, including basic and clinical research, laboratory studies, and animal models. The journal particularly welcomes submissions focusing on identifying and delineating biomarkers associated with cancer risk and prognosis, assessing and validating cancer biomarkers, and understanding the underlying biology, genomics and epigenetics of cancer.

 

The journal also seeks to promote interdisciplinary collaborations between researchers, clinicians, and healthcare professionals. JCGB encourages the submission of manuscripts that contribute to the advancement of cancer genetics and biomarker research and will be of great benefit to the cancer research community and to the wider biomedical science community.

 

Contributions from the following research areas are invited but not limited to the following branches :

• Lymphoma
• Cancer
• Palliative care
• Prognosis
• Diagnosis
• CTC
• Colorectal Cancer
• Osteosarcoma
• Immunotherapy
• Tumor
• Neuroblastoma
• Mutation
• Gene Therapy
• Stem Cells
• Acute lymphocytic leukemia
• Precision medicine
• Biomarkers
• Acute lymphoblastic anemia
• Cytotoxic T-lymphocytes
• Relapsed Cancer
• Cancer genetics
• Biomarkers in cancer
• Genetic testing for cancer
• Personalized cancer treatment
• Genomic medicine in cancer
• Cancer susceptibility genes
• Hereditary cancer syndromes
• Cancer epigenetics
• Tumor suppressor genes
• Oncogenes
• Genetic counseling for cancer
• Cancer gene expression
• Cancer genomics
• Cancer pharmacogenomics
• Molecular markers in cancer
• Cancer risk assessment
• Cancer susceptibility testing
• Cancer genetics and prevention
• DNA mutations in cancer
• Cancer stem cells
• Cancer genotyping
• Cancer proteomics
• Cancer metabolomics
• Cancer biomarker discovery
• Cancer immunogenetics
• Circulating tumor DNA
• Liquid biopsy in cancer
• Next-generation sequencing in cancer
• Cancer gene therapy
• Cancer immunotherapy
• Cancer pharmacogenetics
• Cancer clinical trials
• Cancer prognosis
• Cancer diagnosis
• Cancer screening
• Familial cancer
• Pediatric cancer genetics
• Cancer genome editing
• Cancer bioinformatics
• Tumor heterogeneity
• Cancer omics
• Cancer predisposition syndromes
• Cancer drug resistance genetics
• Epigenetic biomarkers in cancer
• Non-coding RNA in cancer
• Immune checkpoint inhibitors in cancer
• Targeted therapy in cancer
• Cancer gene panels
• Gene fusions in cancer
• Gene expression profiling in cancer